Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
71.4M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
42.8M
-
Shares change
-
+12M
-
Total reported value, excl. options
-
$613M
-
Value change
-
+$176M
-
Put/Call ratio
-
0.21
-
Number of buys
-
68
-
Number of sells
-
-29
-
Price
-
$14.32
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) as of Q2 2023
116 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock as of Q2 2023.
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.8M shares
of 71.4M outstanding shares and own 59.95% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (10.1M shares), Medicxi Ventures Management (Jersey) Ltd (3.76M shares), Carlyle Group Inc. (3.5M shares), Invesco Ltd. (3.33M shares), BlackRock Inc. (2M shares), Avidity Partners Management LP (1.95M shares), Ensign Peak Advisors, Inc (1.76M shares), VANGUARD GROUP INC (1.74M shares), 683 Capital Management, LLC (1.29M shares), and NEA Management Company, LLC (1.28M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.